共 45 条
Therapeutic Effect of Tolerogenic Dendritic Cells in Established Collagen-Induced Arthritis Is Associated With a Reduction in Th17 Responses
被引:128
作者:
Stoop, Jeroen N.
[1
]
Harry, Rachel A.
[1
]
von Delwig, Alexei
[1
]
Isaacs, John D.
[1
]
Robinson, John H.
[1
]
Hilkens, Catharien M. U.
[1
]
机构:
[1] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源:
ARTHRITIS AND RHEUMATISM
|
2010年
/
62卷
/
12期
基金:
英国医学研究理事会;
关键词:
REGULATORY T-CELLS;
RHEUMATOID-ARTHRITIS;
IN-VIVO;
AUTOIMMUNE-DISEASE;
EXPRESS IL-4;
II COLLAGEN;
MICE;
INDUCTION;
JOINT;
INFLAMMATION;
D O I:
10.1002/art.27756
中图分类号:
R5 [内科学];
学科分类号:
100201 [内科学];
摘要:
Objective. Tolerogenic dendritic cells (DCs) are antigen-presenting cells with an immunosuppressive function. They are a promising immunotherapeutic tool for the attenuation of pathogenic T cell responses in autoimmune arthritis. The aims of this study were to determine the therapeutic action of tolerogenic DCs in a type II collagen-induced arthritis model and to investigate their effects on Th17 cells and other T cell subsets in mice with established arthritis. Methods. Tolerogenic DCs were generated by treating bone marrow-derived DCs with dexamethasone and vitamin D3 during lipopolysaccharide-induced maturation. Mice with established arthritis received 3 intravenous injections of tolerogenic DCs, mature DCs, or saline. Arthritis severity was monitored for up to 4 weeks after treatment. Fluorescence-labeled tolerogenic DCs were used for in vivo trafficking studies. The in vivo effect of tolerogenic DCs on splenic T cell populations was determined by intracellular cytokine staining and flow cytometry. Results. Tolerogenic DCs displayed a semi-mature phenotype, produced low levels of inflammatory cytokines, and exhibited low T cell stimulatory capacity. Upon intravenous injection into arthritic mice, tolerogenic DCs migrated to the spleen, liver, lung, feet, and draining lymph nodes. Treatment of arthritic mice with type II collagen-pulsed tolerogenic DCs, but not unpulsed tolerogenic DCs or mature DCs, significantly inhibited disease severity and progression. This improvement coincided with a significant decrease in the number of Th17 cells and an increase in the number of interleukin-10-producing CD4+ T cells, whereas tolerogenic DC treatment had no detectable effect on Th1 cells or interleukin-17-producing gamma/delta T cells. Conclusion. Treatment with type II collagen-pulsed tolerogenic DCs decreases the proportion of Th17 cells in arthritic mice and simultaneously reduces the severity and progression of arthritis.
引用
收藏
页码:3656 / 3665
页数:10
相关论文

